Explore it now
27th Annual ESGO 2026 Congress
Discover it Now!
ENGOT coordinates and promotes gynaecological cancer clinical trials in Europe
Explore ENGOT
Explore ESGO’s Membership Benefits
Read More
When: June 17, 2025Time: 6:00 PM – 7:30 PM CET
Join us for a groundbreaking educational webinar that will walk you through the first international consensus guidelines on the diagnosis, treatment, and follow-up of Gestational Trophoblastic Disease (GTD) — a rare group of pregnancy-related conditions that, when treated appropriately, have excellent prognoses.
Developed collaboratively by four global organizations — the European Organisation for the Treatment of Trophoblastic Diseases (EOTTD), the European Society of Gynaecological Oncology (ESGO), the Gynecologic Cancer InterGroup (GCIG), and the International Society for the Study of Trophoblastic Diseases (ISSTD) — these guidelines aim to standardize the care of GTD patients across borders and elevate the quality of clinical decision-making worldwide.
The consensus represents the collective expertise of 53 clinicians from 31 countries, combining real-world clinical experience and the best available evidence into a practical framework that covers both pre-malignant and malignant forms of GTD, including hydatidiform mole, low-risk and high-risk GTN, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT).
How to implement 18 detailed flow diagrams for diagnosis, primary treatment, recurrence management, and follow-up
The significance of 9 consensus-based clinical definitions that clarify terminology and unify diagnostic standards
Minimum criteria for establishing and operating a GTD referral center
How to recognize and address variations in care that may compromise outcomes
How the guidelines aim to reduce avoidable mortality, improve prognosis, and stimulate global GTD research
Global leaders in trophoblastic disease care will guide you through the most clinically relevant updates and how to translate them into daily practice:
Prof. Michael SecklNavigating the Maze: New Guidelines for Gestational Trophoblastic Disease
Prof. Elena Ioana BraicuFlowing through the Treatment of Hydatidiform Mole
Prof. Antonio BragaLow Risk GTD Guidelines Unpackaged
Prof. Michael SecklHigh Risk GTN in the Modern Age
Prof. Christianne LokAPSN and PSTT/ETT Unplugged
Prof. Ulrika JonebergAn expert in gynecologic oncology, Prof. Joneberg will lead the discussion, moderate the Q&A, and ensure an interactive, engaging learning experience for all participants.
GTD affects approximately 220,000 women worldwide each year, with an estimated 22,000 cases progressing to malignant GTN. Yet, care remains inconsistent across the globe, with some patients receiving suboptimal or unnecessary treatment due to a lack of clear, harmonized guidelines. This initiative provides the tools and direction needed to deliver consistent, high-quality care to all GTD patients—regardless of geography.
Don’t miss this opportunity to be part of a global knowledge-sharing movement that has the potential to save lives and transform care standards for this rare group of diseases.